Development of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish children

Basit Öğe Kaydı
dc.contributor.authorYeşilkaya, Şirzat
dc.contributor.authorAçıkel, Cengizhan
dc.contributor.authorFidancı, Berna Eren
dc.contributor.authorPolat, Adem
dc.contributor.authorSözeri, Betül
dc.contributor.authorAyaz, Nuray Aktay
dc.contributor.authorMakay, Balahan Bora
dc.date.accessioned2020-03-26T19:01:48Z
dc.date.available2020-03-26T19:01:48Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractObjective. To develop and assess the validity and reliability of an adherence scale concerning medical treatment in paediatric FMF patients. Methods. The Medication Adherence Scale in FMF Patients (MASIF) is a 18-item questionnaire that evaluates adherence to medication in four domains. Validation of the instrument was accomplished in paediatric FMF patients (aged 2-18 years) under medication at least for 6 months. The first step was to build up the scale through qualitative approach (with interviews using semi-structured questions). Validation analyses included assessment of feasibility, face and content validity; construct validity, internal consistency and test-retest reliability. Results. One hundred and fifty patients with FMF were enrolled in the study. The mean age of the patients was 11.11 +/- 4.02 years and 48.7% of them were male. The MASIF was found to be feasible and valid for both face and content. It correlated with the Morisky Medication Adherence Scale as a gold standard thereby demonstrating good construct validity (r=0.5 15, p<0.001). Assessment of content validity identified four subscales. The internal consistency, Cronbach's alpha was 0.728. There was a positive and significant correlation between test and retest scores (r-0.843; p<0.001). Also, a significant correlation between parents' and children's reports (r=0.781, p<0.001). Conclusion. Based on these results, the use of this scale to assess and follow up the adherence to treatment in paediatric FMF patients under medical treatment is recommended.en_US
dc.identifier.endpageS162en_US
dc.identifier.issn0392-856Xen_US
dc.identifier.issn1593-098Xen_US
dc.identifier.issue6en_US
dc.identifier.pmid26393894en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpageS156en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/31999
dc.identifier.volume33en_US
dc.identifier.wosWOS:000365834600026en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCLINICAL & EXPER RHEUMATOLOGYen_US
dc.relation.ispartofCLINICAL AND EXPERIMENTAL RHEUMATOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectfamilial Mediterranean feveren_US
dc.subjectcolchicineen_US
dc.subjectadherenceen_US
dc.subjectscaleen_US
dc.titleDevelopment of a medication adherence scale for familial Mediterranean fever (MASIF) in a cohort of Turkish childrenen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu